Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon gamma-1b - Horizon Pharma

Drug Profile

Interferon gamma-1b - Horizon Pharma

Alternative Names: Actimmune; IFNγ-1b; Imukin; Interferon-gamma-1b

Latest Information Update: 28 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Fox Chase Cancer Center; Friedreichs Ataxia Research Alliance; Horizon Pharma; InterMune
  • Class Antineoplastics; Antivirals; Interferons; Lymphokines
  • Mechanism of Action Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic granulomatous disease; Pulmonary fibrosis; Friedreich's ataxia; Renal cell carcinoma; Osteopetrosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic granulomatous disease; Osteopetrosis
  • Phase I/II Breast cancer
  • No development reported Hepatitis B; Hepatitis C; Solid tumours
  • Discontinued Atopic dermatitis; Cryptococcosis; Friedreich's ataxia; Hepatic fibrosis; Keloids; Mycoses; Non-Hodgkin's lymphoma; Ovarian cancer; Pulmonary fibrosis; Renal cell carcinoma; Systemic scleroderma; Tuberculosis

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC, Injection)
  • 25 Jul 2018 Interferon gamma-1b (Imukin®) licensed to Clinigen, worldwide
  • 08 May 2017 Horizon plans a clinical trial, in collaboration with the National Cancer Institute for Cutaneous T-Cell lymphoma (Combination therapy) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top